Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

Dan O’Day’s $5B deal with Gala­pa­gos im­plodes as PhI­II tri­als col­lapse

Gilead’s bat­tle-scarred al­liance with Gala­pa­gos just suf­fered an­oth­er griev­ous wound.

The biotech part­ners re­port­ed Wednes­day morn­ing that they are aban­don­ing their late-stage piv­otal pro­gram for zir­i­tax­e­s­tat (GLPG1690) — along with every­thing else in the clin­ic — af­ter the drug failed a fu­til­i­ty analy­sis, the lat­est in a se­ries of big set­backs to af­flict these play­ers.

This drug was at the heart of Dan O’Day’s re­vised al­liance with Gala­pa­gos back in the sum­mer of 2019, as the then new­ly-named Gilead CEO looked to di­ver­si­fy the pipeline and sat­is­fy an­a­lysts’ de­mands for a broad­er prod­uct port­fo­lio with what he called a “trans­for­ma­tive” pact. Gilead paid close to $5 bil­lion in an up­front and eq­ui­ty in­vest­ment for that deal, which now large­ly lies in ru­in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.